Abstract: Erectile dysfunction (ED) has long been described by physicians and patients, with treatments for ED proposed starting in the 8 th century BC. In the last 50 years, however, there have been many advances 
Introduction
Erectile dysfunction (ED), the inability to achieve or maintain an erection sufficient for sexual performance, has been described for centuries. ED has numerous psychological and social implications, can diminish selfesteem and quality of life, and can negatively impact female partner sexual function (1) . The first accounts of ED treatment come from medieval Islamic physicians in the 8 th century BC who tried herbs, prayer, topical and intraurethral treatments and multi-modality therapies with limited success. The treatment of ED has been of interest to physicians since then and has appeared in historical documents such as The Canon of Medicine and The Comprehensive book on Medicine (2, 3) . Accounts of ED also appear in the Old Testament as well as in sacred Hindu texts.
Hippocrates famously declared that being worried about business and unattractive women caused ED (4) . Today, it is estimated that as many as 52% of men between the ages of 40-70 experience some degree of ED (5) . ED has many etiologies that can be divided into organic and psychological categories. Psychological causes of ED include depression, anxiety, relationship trouble, and past history of sexual abuse, among others. Organic etiologies of ED are most commonly vascular or mechanical. Many chronic conditions including hypertension, metabolic syndrome, diabetes, smoking and hypercholesterolemia can contribute to a vascular cause of ED, and are also associated with coronary artery disease, to which ED is inextricably linked (6) . Lastly, men with penile injury, Peyronie's disease, spinal cord injuries or testosterone deficiency can also experience ED (7) .
Over the past 3 decades, many novel, effective therapies to treat ED have been implemented, most notably About 3 to 4 weeks later, the tube was divided to create a penis and a urethra was fashioned. Despite these attempts, this procedure was fraught with many complications and was often only effective for 18 months to 4 years, when the cartilage would fold on itself or be absorbed by the body (4, 12) . American physician Dr. Peter L. Scardino is most likely the first to use a synthetic implant but his work was never published. Thus, Willard E. Goodwin and William Wallace Scott are credited with placement of the first acrylic penile implants in 1952 (11) . Many advances in surgical technique and materials during the 1960s and 1970s, including the use of silicone as a surgical material facilitated the rise of inflatable penile implants. Dr. GE Beheri, an Egyptian surgeon, was the first to use intracavernosal polyurethane rods placed within the tunica albuginea after dilation. This approach was successful and Dr. Beheri performed over 700 procedures. The new material bettered the results and lessened side effects but because Dr. Beheri was a plastic surgeon and published in plastic surgery journals, the procedure did not gain significant traction in the urologic community (11, (13) (14) (15) . The last development in technology that led to the current IPP can be credited to the National Aeronautics and Space Administration (NASA), which developed a high-grade silicone as part of the space program that was subsequently used by American doctors for penile implants. A silicone implant was first tried by RO Pearman when he placed it between Buck's fascia and the tunica albuginea, but was ultimately unsuccessful because of significant post-operative pain. Subsequent placement within the tunica albuginea, much like the work of Beheri, was successful. These advances all eventually led to the development of the precursor to the contemporary IPP, developed by F. Brantley Scott, a urologist at Baylor College of Medicine, and introduced in 1973 (11, 16) .
The evolution of the modern IPP
In 1974, just a year after Dr. Scott's revolutionary inflatable device, was introduced to the market, Drs. Michael Small and Hernan Carrion introduced their competitor device: a precursor to semirigid malleable devices that are popular in other parts of the world. The device consisted of two sponge-filled, silicone-covered rods. After the initial semirigid malleable device was introduced, other devices also became available. Notably, the Jones-ESKA silicone prosthesis, silver prosthesis, Mentor Accuform prosthesis, and the AMS 600 all were introduced during the 1980s (17, 18) . While improved versions of these devices are used in other countries, the semirigid devices do not allow for a natural appearing flaccid state and are infrequently used in the United States (11, 19, 20) .
The original design of the IPP included two inflatable silicone rods, a welcome departure from previous semirigid designs. In his initial description in July 1973, Dr. Scott described his device as composed of two inflatable silicone bodies, a reservoir and a control pump. Through a series of four case reviews of his first five patients, Dr. Scott laid the groundwork for a very promising, long-term solution for ED (11, 21) . Dr. Scott marketed the first generation of IPPs through AMS, a company that he helped found. Though initially referred to as the inflatable penile implant, when AMS began marketing the device, the name was changed to the AMS 700 (11, 15) . Like most first iterations of a device, initial design problems became apparent with use, most of which have been remedied over the last 40 years (see Table 1 ).
Initial AMS devices
The first version of the IPP suffered from suboptimal device lifetimes and rigidity, with a 61% complication or revision rate at 3-11 years after placement (22) . Changes to the initial design of the AMS 700 between 1983-1987 included placement of caps on both ends of the cylinders and the development of a suture-less fluid containment system, which decreased inter operator variability in preventing leaks (23) . A major advance came in 1986 when kinkresistant tubing (KRT) was added, permitting less precise intraoperative measurements and simplifying the insertion procedure. Polytetrafluoroethylene (PTFE) sleeves were also added to increase the durability and lifespan of the device, and to prevent adhesion to the corporal tissues. While more durable, the filling of the sleeves was restricted by the patient's corpus cavernosum and therefore resulted in aneurysmal dilation. In 1987, the PTFE sleeves were replaced by a multilayer design. This 3-ply system in the new AMS 700 CX ® used both an inner silicone coating and a woven silicone layer that allowed for reduced friction and easier inflation, reducing resistance to filling that had previously led to dilation (11, 16, 21) . These alterations to the device improved the procedure dramatically; the 61% complication rate in patients operated on before 1983 was reduced to only 13% for those who received an AMS 700 after 1983 (23, 24) . The AMS 700CX was again evaluated in 2000 when Carson et al. found that in 372 patients the mechanical reliability of the device was 86.2%±4.6% after 5 years with infection in 3.2% of patients (23, 25) . In 2000, AMS debuted a parylene coating that further dramatically reduced friction, better mimicking an organic erection (11, 26) . The pump of the AMS 700 has also been a target for improvement. AMS updated their pump design with the momentary squeeze (MS) pump. The pump contains a oneway valve that requires squeezing the deflate button for 3-4 s to activate, and prevents unintentional inflation (23) . AMS also now makes several models of IPP cylinders for use on men with smaller phalluses (AMS 700 CXM ® requiring 11 mm dilation) or other anatomical abnormalities such as fibrosis (AMS 700 CXR ® , 9 mm dilation) that previously were a challenge to place a device in (16, 23, 27) . There has been interest in increasing penile length and girth since the advent of the IPP, and the AMS Ultrex (now LGX ® ) had an expandable middle layer but was ultimately unsuccessful because of poor material reliability and durability, with a resulting suboptimal device performance. Furthermore, the Ultrex was not as effective in patients with anatomic disease such as Peyronie's disease and the preferred device for these patients is its predecessor, the AMS CX/CXR ® (28,29).
AMS's second attempt at a prosthesis that could expand in both length and girth was the AMS LGX ® , which allowed a 25% increase in penile length and girth (27) . While AMS was the first company to market IPP, the market changed in 1983 when Mentor (now Coloplast) entered the arena.
Mentor devices
The most significant modification that the Mentor company made to the 3-piece IPP system was the use of different materials from the AMS IPP models. Rather than using silicone, the Mentor device cylinders were initially made from polyurethane. Later, Mentor patented the Bioflex ® material (30, 31) . Bioflex ® had many advantages over silicone cylinders, with perhaps the most significant being a 7-fold higher tensile strength, while maintaining biocompatibility. Bioflex ® also had a more limited ability to expand, in contrast with silicone models that were prone to excessive dilation (31) . Shortly after the introduction of Bioflex ® , Mentor added a Bioflex ® reservoir connected using silicone KRT (11, 16, 31, 32) . The Bioflex ® IPP models have demonstrated impressive long-term durability, with 88% of devices functional after 10 years of use (11, 23) . In 1987, Mentor unveiled an updated model that included a modified pump, the addition of nylon to improve the KRT, and caps on the rear tip extenders to improve durability (16, 32 
IPP enhancements since 1990
In 1993, AMS further improved the 700 Ultrex IPP by strengthening the middle fabric layer after reports of tears by adding a stronger fabric weave (23, 28) . This modification was studied in 2000 when a group from the Cleveland Clinic compared patients who received the original and enhanced implant (85 and 52 patients, respectively). The 5-year Kaplan-Meier estimates of overall device survival were 64.7% in the original devices and 77.7% in the enhanced devices (P=0.23). Mechanical device survival at 5 years was 70.7% for the original and 93.7% for the enhanced device (P=0.017), and cylinder survival was 80.2% and 96.2% for the two groups, respectively (P=0.008) (27) . In 1988, Mentor released the Mentor GSF prosthesis, a 2-piece device later renamed the Mark II after tubing connectors were eliminated from the design. The most recent 2-piece design produced by Coloplast is the Excel model, which is only used outside the United States (34) . In 1994, AMS released Ambicor IPP, a 2-piece device that included cylinders and a connected pump. While the placement procedure using these devices was shorter because there was no reservoir to place, the devices did not inflate as well without a reservoir to store additional fluid, and did not achieve the rigidity of three piece IPPs (23) . In 2000, Mentor introduced the lock-out valve, designed to stop IPP auto-inflation resulting from increased intraabdominal pressure. Before the introduction of the lockout valve, auto-inflation was reported in 11% of cases, with 2% requiring surgical revision. While generally a benign problem, auto-inflation can cause embarrassment and inconvenience, and in rare cases can cause device breakdown (35 . At 180 days, the infection rates in the treated and control groups were 0.68% and 1.61%, respectively (P=0.0047), a 57.8% reduction in infection rates (37) . In 2002 Mentor introduced another improvement with the goal of reducing postoperative infection rates-the Titan ® -which had cylinders coated with a hydrophilic substance that decreases bacterial adherence and can absorb and release antibiotics. In a 2004 study by Wolter et al., Titan devices were observed to have a 1-year infection rate of 1.06% across 2,357 patients, compared with a 2.07% infection rate seen in 482 patients implanted with alpha-1 devices. Staphylococcus bacterial species were the major infectious agent in both groups (23, 38) . In 2011, Dhabuwala et al. compared Titan implants coated with vancomycin/gentamycin or rifampin/ gentamicin, and Inhibizone-impregnated (AMS) implants to examine rates of infection. The Titan implant with vancomycin/gentamycin had an infection rate of 4.4% and the Inhibizone implant had a rate of 1.3% (P=0.05).
The Titans with rifampin/gentamycin had no infections reported. This suggests rifampin as the best antibiotic to be used (39) . In 2006, the Mentor company was purchased by Coloplast, which allowed Coloplast to expand into men's urologic health.
Evolution of operative techniques
Implantation techniques for penile prostheses have undergone numerous iterative improvements as devices have become more durable and reliable. Both AMS and Coloplast IPPs offer variably colored tubing to facilitate identification of connections between cylinders, pump, and reservoir. The Scott retractor and hooks facilitate device placement, and the Furlow introducer and Keith needle further simplify the procedure by facilitating cylinder placement (11, 24) . Carrion-Rossello cavernotomes now permit gradual dilation of fibrotic corpora, decreasing the risk of perforation (40) . As physicians have become more skilled at IPP placement, alternative reservoir sites have been introduced. In most cases, the reservoir is placed retroperitoneally in the space of Retzius. However, in the setting of prior surgery or concern for trauma to intraabdominal organs, alternative reservoir placement sites have grown in popularity. Today, IPP reservoirs can be placed ectopically, between the transversalis fascia and rectus muscle (41) . Reservoir design has followed suit, with AMS introducing its flattened Conceal ® reservoir in 2006 and more recently, Coloplast unveiled the Cloverleaf ® reservoir (11, 42) .
Limitations to penile prosthetics
While penile prosthetics have come a long way since 1973, there remain numerous limitations and areas for improvement. Only 5% of eligible patients undergo IPP placement, for reasons including expense, fear of surgery or complications, and that having to inflate and deflate the device feels unnatural (11, 43) . Compared to other ED treatment modalities, IPP requires more down time after placement and carries the risk of infection and anesthesia complications, like any other surgical procedure. Another limitation that has received attention from the media in the last 10 years is cost, and who should pay for these devices. Currently, devices range in price from $8,000-$14,000, with coverage by Medicare. One of the major limitations to IPPs is comfort. In 2013, Hakky et al. created 3D models of human cadaveric corpora cavernosa and compared them to two different models of Coloplast Titan IPPs to assess how well the device mimicked the natural penile anatomy. They found subtle differences in shape, especially at the distal end of the device. This is an area of ongoing research and remains a limitation of current IPPs (44, 45) . As microbial resistance continues to emerge, the IPP will need to continue evolving to stay ahead of complication postoperative infections.
Conclusions
Penile prostheses as a treatment for ED have come a long way since 8 th century BC spiritual and herbal approaches.
From the original malleable implants, to the modern inflatable 3-piece prosthetics with durable, reliable fluid systems and integrated infection control mechanisms, the device has significantly improved since the 1980s. With these iterative improvements have come a decrease in complication rates and an increase in patient satisfaction rates. While novel medical therapies for ED, such as gene therapy and treatments targeting novel erectile pathways hold promise, the IPP remains a durable, reliable, contemporary approach to successfully treating men with ED refractory to current medical therapies.
